Alexion Pharmaceuticals, a clinical stage biopharmaceutical company focusing on the development of life-transforming therapies for patients with devastating and rare diseases, recently announced positive results from a phase 3 study of their second generation of Soliris® (ALXN1210), for the treatment of PNH. The press release announcing these results can be read here.
According to the news release, the study showed that PNH patients can be effectively and safely switched from treatment with Soliris® (eculizumab) every two weeks to treatment with ALXN1210 every eight weeks; providing a treatment schedule that would be significantly more convenient for patients. The study held included clinical trial sites in Edmonton and Toronto, Canada.
After reaching out to the company for an update, the Canadian Association of PNH Patients has learned that Alexion Pharmaceuticals has submitted ALXN1210 for regulatory approval in Canada and expects a decision in the second half of 2019.